Literature DB >> 10067700

The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1.

Z Papp1, L A Babiuk, M E Baca-Estrada.   

Abstract

We investigated whether pre-existing adenovirus-specific immunity influenced the development of immunity to a foreign antigen expressed by recombinant adenovirus. Active adenovirus-specific immunity was induced in cotton rats by i.n. administration of wild type human adenovirus type 5 (HAd5) two weeks before immunisation with a HAd5 vector expressing the glycoprotein D (gD) of bovine herpesvirus type 1 (gD-dE3 recombinant adenovirus). Active adenovirus-specific immunity inhibited gD-specific immune responses, following either i.n. or gastrointestinal immunisation with gD-dE3. An inhibitory effect was present even if infection with HAd5 and immunisation with gD-dE3 were 13 weeks apart. Passive transfer of adenovirus specific antibodies to cotton rats one day before immunisation, however, did not significantly inhibit gD-specific immune responses induced by i.n. immunisation with gD-dE3. Repeated administration of an adenovirus vector, therefore, may have a limited ability to deliver antigen, while passive immunity to adenovirus may not interfere with the success of immunisation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067700     DOI: 10.1016/s0264-410x(98)00279-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors.

Authors:  S Mandl; L Hix; R Andino
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Handling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.

Authors:  Breanne Cuddington; Meghan Verschoor; Karen Mossman
Journal:  J Vis Exp       Date:  2014-11-24       Impact factor: 1.355

Review 5.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

6.  A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque.

Authors:  Jianping Lin; Roberto Calcedo; Luk H Vandenberghe; Peter Bell; Suryanarayan Somanathan; James M Wilson
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

7.  An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.

Authors:  E S Gabitzsch; Y Xu; S Balcaitis; J P Balint; F R Jones
Journal:  Cancer Gene Ther       Date:  2011-01-14       Impact factor: 5.987

8.  Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.

Authors:  Maria A Croyle; Ami Patel; Kaylie N Tran; Michael Gray; Yi Zhang; James E Strong; Heinz Feldmann; Gary P Kobinger
Journal:  PLoS One       Date:  2008-10-29       Impact factor: 3.240

9.  Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.

Authors:  Sunil K Khattar; Sweety Samal; Celia C LaBranche; David C Montefiori; Peter L Collins; Siba K Samal
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

10.  Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus.

Authors:  Vinoth K Manoharan; Sunil K Khattar; Celia C LaBranche; David C Montefiori; Siba K Samal
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.